American Society of Hematology

Figure 1.

$Forest plot of ORR by IRC assessment (N = 32).a2-sided Clopper-Pearson 95% confidence intervals. bMIPI score was calculated with cutoffs as low (<5.7), intermediate (5.7 to <6.2), and high (≥6.2). cDerived from baseline tumor biopsy/aspiration per investigator assessment. dExtranodal disease is defined as patients with extranodal baseline target or nontarget lesions, or bone marrow involvement by biopsy per investigator assessment. eRefractory disease is defined as best overall response of stable disease or progressive disease from last prior anti-cancer treatment regimen. Hyper-CVAD, cyclophosphamide, vincristine, doxorubicin, cytarabine, methotrexate, and Ara C; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; LDi, longest transverse diameter of a lesion; MIPI, MCL International Prognostic Index.$

Forest plot of ORR by IRC assessment (N = 32).^a2-sided Clopper-Pearson 95% confidence intervals. ^bMIPI score was calculated with cutoffs as low (<5.7), intermediate (5.7 to <6.2), and high (≥6.2). ^cDerived from baseline tumor biopsy/aspiration per investigator assessment. ^dExtranodal disease is defined as patients with extranodal baseline target or nontarget lesions, or bone marrow involvement by biopsy per investigator assessment. ^eRefractory disease is defined as best overall response of stable disease or progressive disease from last prior anti-cancer treatment regimen. Hyper-CVAD, cyclophosphamide, vincristine, doxorubicin, cytarabine, methotrexate, and Ara C; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; LDi, longest transverse diameter of a lesion; MIPI, MCL International Prognostic Index.

This Feature Is Available To Subscribers Only